LYCOS RETRIEVER 
Hepatitis C: Loss
built 255 days ago
Abstract Summary: PSI-6130 is the parent molecule of the prodrug R7128, an orally active inhibitor of the hepatitis C virus NS5B polymerase currently in clinical development. Proprietary and public database containing HCV NS5B sequences representing six HCV genotypes were analyzed for the presence of the S282T substitution. S282T results in a small loss in the antiviral activity of PSI-6130 and is not highly polymorphic in the wild-type HCV population. These in vitro data indicate that there is a high genetic barrier to resistance to PSI-6130. Since PSI-6130 is metabolized to two active triphosphate forms, it is enticing to speculate that the two structurally different active metabolites would further increase the genetic barrier of PSI-6130.
Source:
Viral Hepatitis - Viral hepatitis refers to hepatitis caused by a few specific viruses that primarily attack the liver. Hepatitis symptoms include loss of appetite, nausea, vomiting, fever, weakness, tiredness, and abdominal pain. Source:MedicineNet
Source:
Many people infected with hepatitis C have no symptoms. When symptoms are present, they can range from mild to severe. The most common early symptoms are mild fever, headache, muscle aches, fatigue, loss of appetite, nausea, vomiting and diarrhea. Later symptoms may include dark coffee-colored rather than dark yellow urine, clay-colored stools, abdominal pain, and yellowing of the skin and/or whites of the eyes (jaundice).
Source:
MORE ABOUT
Loss